These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26694454)

  • 21. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
    Zoulim F; Moreno C; Lee SS; Buggisch P; Horban A; Lawitz E; Corbett C; Lenz O; Fevery B; Verbinnen T; Shukla U; Jessner W
    Virol J; 2018 Jan; 15(1):26. PubMed ID: 29378602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profile of alisporivir and its potential in the treatment of hepatitis C.
    Gallay PA; Lin K
    Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
    Li Z; Chen ZW; Ren H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
    Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
    Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
    Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T
    PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
    Sullivan JC; De Meyer S; Bartels DJ; Dierynck I; Zhang EZ; Spanks J; Tigges AM; Ghys A; Dorrian J; Adda N; Martin EC; Beumont M; Jacobson IM; Sherman KE; Zeuzem S; Picchio G; Kieffer TL
    Clin Infect Dis; 2013 Jul; 57(2):221-9. PubMed ID: 23575197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection.
    Huang W; Wang M; Gong Q; Yu D; Chen P; Lin J; Han Y; Su Y; Qu L; Zhang X
    Microb Drug Resist; 2019; 25(6):944-950. PubMed ID: 30702389
    [No Abstract]   [Full Text] [Related]  

  • 35. Direct acting antivirals failure: cause and retreatment options.
    Parlati L; Pol S
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.
    Santos APT; Silva VCM; Mendes-Corrêa MC; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; Castro VFD; Pinho JRR; Moreira RC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e61. PubMed ID: 36197422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
    Fahnøe U; Pedersen MS; Sølund C; Ernst A; Krarup HB; Røge BT; Christensen PB; Laursen AL; Gerstoft J; Thielsen P; Madsen LG; Pedersen AG; Schønning K; Weis N; Bukh J
    J Viral Hepat; 2021 Feb; 28(2):302-316. PubMed ID: 33131178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.
    Stirnimann G
    Expert Opin Pharmacother; 2014 Dec; 15(17):2609-22. PubMed ID: 25347030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.
    Jeong Y; Jin B; Lee HW; Park HJ; Park JY; Kim DY; Han KH; Ahn SH; Kim S
    J Viral Hepat; 2018 Nov; 25(11):1251-1259. PubMed ID: 29768695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus resistance to the new direct-acting antivirals.
    Esposito I; Trinks J; Soriano V
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.